ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Drug Interaction Study of Isavuconazole and Midazolam
Phase 1
Completed
- Conditions
- Pharmacokinetics of IsavuconazolePharmacokinetics of MidazolamHealthy Volunteers
- Interventions
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01406171
- Locations
- 🇺🇸
Covance Clinical Research, Madison, Wisconsin, United States
A Study to Assess the Pharmacokinetics of ASP015K in Healthy Male Subjects
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 6
- Registration Number
- NCT01406132
- Locations
- 🇺🇸
Covance Clinical Research Unit (CCRU), Madison, Wisconsin, United States
A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 60
- Registration Number
- NCT01406145
- Locations
- 🇺🇸
MD Clinical, Hallandale Beach, Florida, United States
🇺🇸Pacific Research Network, Inc., San Diego, California, United States
To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)
Phase 1
Completed
- Conditions
- Pharmacokinetics of Darexaban and MetabolitesHealthy Subjects
- Interventions
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2014-03-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 26
- Registration Number
- NCT01405989
- Locations
- 🇫🇷
SGS Aster, Paris, France
To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)
Phase 1
Completed
- Conditions
- Pharmacokinetics of Darexaban and MetabolitesHealthy Subjects
- Interventions
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 26
- Registration Number
- NCT01406002
- Locations
- 🇫🇷
SGS Aster, Paris, France
A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration
Phase 1
Completed
- Conditions
- HealthyPharmacokinetics of ASP1941Pharmacokinetics of Mitiglinide
- Interventions
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 60
- Registration Number
- NCT01403818
Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2014-06-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 29
- Registration Number
- NCT01401504
A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 36
- Registration Number
- NCT01394653
A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2011-07-13
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 36
- Registration Number
- NCT01392794
A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)
Phase 2
Completed
- Conditions
- Chronic Abacterial ProstatitisChronic Pelvic Pain Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 239
- Registration Number
- NCT01391338
- Locations
- 🇪🇸
Site: 3701 - Hospital Moises Broggi de Sant Joa, Barcelona, Spain
🇵🇱Site: 3505 - EMC Instytut Medyczny SA, Wroclaw, Poland
🇪🇸Site: 3703 - Fundació Puigvert, Barcelona, Spain
© Copyright 2025. All Rights Reserved by MedPath